HEALTHCARE GAPS IN T2D: PREVALENCE AND CHARACTERISTICS OF INADEQUATE CARE IN THE UNITED STATE
Abstract
Type 2 Diabetes Mellitus (T2D) stands as an escalating epidemic in the United States (US), affecting over 30 million diagnosed individuals, with an additional 34% of the adult population deemed prediabetic. This pervasive health issue not only leads to a 10-year reduction in life expectancy upon diagnosis but also incurs an additional $9,600 in direct medical costs per diabetes patient. The imperative to address T2D lies not only in the financial burden but also in the potential complications that arise due to inadequate management. Diabetesrelated complications encompass both microvascular (nephropathy, neuropathy, and retinopathy) and macroscopic (heart disease, stroke, and peripheral artery disease) complications, posing significant risks to individuals with T2D. The severity of these risks is underscored by the fact that people with T2D face twice the likelihood of mortality from cardiovascular disease compared to those without T2D. Hence, effective T2D management necessitates not only glycemic control but also vigilant screening and treatment of diabetes-related complications. This abstract synthesizes the alarming statistics and healthcare implications associated with T2D in the US. The escalating prevalence, coupled with the substantial economic and health burdens, underscores the urgency for comprehensive T2D management strategies. By delving into the array of complications linked to T2D, from microvascular to macroscopic, the abstract emphasizes the multifaceted nature of the risks associated with poor T2D management. Beyond glycemic control, it emphasizes the critical role of screening and timely intervention to mitigate diabetes-related complications and improve overall health outcomes for individuals with T2D.
Keywords:
Type 2 Diabetes Mellitus (T2D), Complications, Disease Management, Prediabetes, Cardiovascular RiskDownloads
Published
DOI:
https://doi.org/10.5281/zenodo.10568788%20Issue
Section
How to Cite
License
Copyright (c) 2024 Dr. Sarah Sansgiry , Prof. Dr. James K. Williamson

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA, U.S. Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, 2020.
American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. Published online March 21, 2018. doi:10.2337/dci18-0007
Wang Z, Liu M. Life years lost associated with diabetes: An individually matched cohort study using the U.S. National Health Interview Survey data. Diabetes Res Clin Pract. 2016; 118: 69-76. doi:10.1016/j.diabres.2016.06.015
Papatheodorou K, Banach M, Bekiari E, Rizzo M, Edmonds M. Complications of Diabetes 2017. J Diabetes Res. 2018;2018. doi:10.1155/2018/3086167
National Institute of Diabetes and Digestive and Kidney Diseases Diabetes, Heart Disease, and Stroke Bethesda, MD, U.S. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 2017
American Diabetes Association. Standards of Medical Care in Diabetes—2018. Dia Care. 2018;41(Supplement 1):S3-S3. doi:10.2337/dc18-Sppc01
Delevry D, Ho A, Le QA. Association between processes of diabetes care and health care utilization in patients with diabetes: Evidence from a nationally representative US sample. Journal of Diabetes. 2021;13(1):7888. doi:https://doi.org/10.1111/1753-0407.13109
Phillips LS, Branch WT, Cook CB, et al. Clinical Inertia. Ann Intern Med. 2001;135(9):825. doi:10.7326/00034819-135-9-200111060-00012
Brunton S. Therapeutic Inertia is a Problem for All of Us. Clinical Diabetes. 2019;37(2):105-106. doi:10.2337/cd19-0009
Moser M. Physician or clinical inertia: what is it? Is it really a problem? And what can be done about it? J Clin Hypertens (Greenwich). 2009;11(1):1-4. doi:10.1111/j.1751-7176.2008.00047.x
Calvin JE, Shanbhag S, Avery E, Kane J, Richardson D, Powell L. Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). Congest Heart Fail. 2012;18(2):73-78. doi:10.1111/j.1751-7133.2011.00263.x
Knighton AJ, McLaughlin M, Blackburn R, et al. Increasing Adherence to Evidence-Based Clinical Practice. Quality Management in Healthcare. 2019;28(1):65-67. doi:10.1097/QMH.0000000000000195 Nagpal J, Sachdeva A, Sengupta Dhar R, Bhargava VL, Bhartia A. Widespread non-adherence to evidencebased maternity care guidelines: a population-based cluster randomised household survey. BJOG. 2015;122(2):238-247. doi:10.1111/1471-0528.13054
O’Connor PJ, Sperl-Hillen JM, Johnson PE, Rush WA, Biltz G. Clinical Inertia and Outpatient Medical Errors. In: Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Advances in Patient Safety. Agency for Healthcare Research and Quality (US); 2005. Accessed December 10, 2019. http://www.ncbi.nlm.nih.gov/books/NBK20513/
Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey Home. [internet] 2021. Available from: https://www.meps.ahrq.gov/mepsweb/ Accessed November 1, 2021
Agency for Healthcare Research and Quality. MEPS HC-201 2017 Full Year Consolidated Data File. [internet] 2019 Available from:
https://meps.ahrq.gov/data_stats/download_data/pufs/h201/h201doc.pdfAccessed November 1, 2021
Agency for Healthcare Research and Quality. MEPS A Survey About Your Diabetes Care [internet] 2019. Available from: https://meps.ahrq.gov/survey_comp/hc_survey/paper_quest/2018/2018_DCS_ENG.shtml Accessed November 1, 2021
National Library of Medicine. Multum MediSource Lexicon (MMSL) Source Information. [internet] 2021 Available from: https://www.nlm.nih.gov/research/umls/rxnorm/sourcereleasedocs/mmsl.html Accessed:
November 1, 2021
US Food and Drug Administration. National Drug Code Directory. [internet] 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory Accessed: November 1, 2021
The National Center for Health Statistics (NCHS) ICD - ICD-10-CM - International Classification of Diseases, Tenth Revision, Clinical Modification. [internet], 2020. Available from:
https://www.cdc.gov/nchs/icd/icd10cm.htm Accessed: November 1, 2021
Agency for Healthcare Research and Quality. MEPS HC-207. [internet] 2019 Available at: https://www.meps.ahrq.gov/data_stats/download_data/pufs/h207/h207doc.shtml
Agency for Healthcare Research and Quality. MEPS HC-206A. [internet] 2019 Available at: https://www.meps.ahrq.gov/data_stats/download_data/pufs/h206a/h206adoc.shtml Accessed November 1, 2021
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998 Jan;36(1):8-27. doi: 10.1097/00005650-199801000-00004. Department of Health and Human Services Federal Poverty Level (FPL) [internet] 2021 Available from: https://www.healthcare.gov/glossary/federal-poverty-level-fpl/ Accessed November 1, 2021
Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI)—Update and ICD-10 translation. Journal of Diabetes and its Complications. 2017;31(6):1007-1013. doi:10.1016/j.jdiacomp.2017.02.018
Andersen RM. Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? Journal of Health and Social Behavior. 1995;36(1):1-10. doi:10.2307/2137284
Liu Y, De A. Multiple Imputation by Fully Conditional Specification for Dealing with Missing Data in a Large Epidemiologic Study. Int J Stat Med Res. 2015;4(3):287-295. doi:10.6000/1929-6029.2015.04.03.7
Hatef E, Vanderver BG, Fagan P, Albert M, Alexander M. Annual diabetic eye examinations in a managed care Medicaid population. Am J Manag Care. 2015;21(5):e297-302.
Centers for Medicare & Medicaid Services. 2018 Value-Based Payment Modifier Program Experience Report. Baltimore, MD Centers for Medicare & Medicaid Services. Department of Health and Human Services, 2018
Imai C, Li L, Hardie RA, Georgiou A. Adherence to guideline-recommended HbA1c testing frequency and better outcomes in patients with type 2 diabetes: a 5-year retrospective cohort study in Australian general practice. BMJ Qual Saf. Published online February 4, 2021. doi:10.1136/bmjqs-2020-012026
Lian J, Liang Y. Diabetes management in the real world and the impact of adherence to guideline recommendations. Curr Med Res Opin. 2014;30(11):2233-2240. doi:10.1185/03007995.2014.952716 32. Villarroel MA. Vaccination Coverage Among Adults With Diagnosed Diabetes: United States, 2015. 2016;(265):8.
Jiménez-Garcia R, Lopez-de-Andres A, Hernandez-Barrera V, et al. Influenza vaccination in people with type 2 diabetes, coverage, predictors of uptake, and perceptions. Result of the MADIABETES cohort a 7years follow up study. Vaccine. 2017;35(1):101-108. doi:10.1016/j.vaccine.2016.11.039
Eppley SE, Mansberger SL, Ramanathan S, Lowry EA. Characteristics Associated with Adherence to Annual Dilated Eye Examinations among US Patients with Diagnosed Diabetes. Ophthalmology. 2019; 126(11):1492-1499. doi:10.1016/j.ophtha.2019.05.033
Paksin-Hall A, Dent ML, Dong F, Ablah E. Factors contributing to diabetes patients not receiving annual dilated eye examinations. Ophthalmic Epidemiol. 2013;20(5):281-287. doi:10.3109/09286586.2013.789531
Peraj E, Subhani MR, Jeong J, Vaknin OS, Twarog JP. Characteristics among adult patients with diabetes who received a foot exam by a health care provider in the past year: An analysis of NHANES 2011-2016. Prim Care Diabetes. 2019;13(3):242-246. doi:10.1016/j.pcd.2018.11.004 Okemah J, Peng J, Quiñones M. Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review. Adv Ther. 2018;35(11):1735-1745. doi:10.1007/s12325-018-0819-5
Bloom F, Yan X, Stewart W, et al. Primary Care Diabetes Bundle Management: 3-Year Outcomes for Microvascular and Macrovascular Events. Am J Manag Care. 2014;20(6):e175-e183.
Kelley E. All or none measurement: why we know so little about the comprehensiveness of care. International Journal for Quality in Health Care. 2007;19(1):1-3. doi:10.1093/intqhc/mzl066
Mangione CM, Gerzoff RB, Williamson DF, et al. The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med. 2006;145(2):107-116. doi:10.7326/00034819145-2-200607180-00008
American Diabetes Association. 1. Strategies for Improving Care. Diabetes Care. 2016;39(Supplement 1):S6S12. doi:10.2337/dc16-S004
Wan EYF, Fung CSC, Jiao FF, et al. Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme–Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses—A Population-Based and Propensity-Matched Cohort Study. Diabetes Care. 2018;41(1):49-59. doi:10.2337/dc17-0426
Ortegon MM, Redekop WK, Niessen LW. Cost-Effectiveness of Prevention and Treatment of the Diabetic Foot: A Markov analysis. Diabetes Care. 2004;27(4):901-907. doi:10.2337/diacare.27.4.901
Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283(7):889-896. doi:10.1001/jama.283.7.889
Canedo JR, Miller ST, Schlundt D, Fadden MK, Sanderson M. Racial/Ethnic Disparities in Diabetes Quality of Care: the Role of Healthcare Access and Socioeconomic Status. J Racial Ethn Health Disparities. 2018;5(1):7-14. doi:10.1007/s40615-016-0335-8